OYAGEN INC.

OYAGEN INC. is a dynamic biotechnology company dedicated to discovering, developing, and commercializing innovative pharmaceutical therapies. With exclusive rights to cutting-edge technologies from leading institutions such as the University of Rochester Medical Center (URMC), Thomas Jefferson University (TJU), and Oregon Health Science Center, OYAGEN is at the forefront of RNA and DNA editing enzyme research.

Based in Henrietta, NY, with a primary address at 77 Ridgeland Rd., Henrietta, NY 14623, US, OYAGEN is focused on harnessing the power of editing enzymes to create groundbreaking treatments for various diseases. The company's initial therapeutic focus is on a novel approach to combatting Human Immunodeficiency Virus (HIV), driven by discoveries related to editing enzymes in the immune system and their interaction with HIV. OYAGEN's strategy includes proprietary assays and high-throughput screening to develop anti-HIV drugs targeting Vif and APOBEC3G, addressing the critical issue of viral resistance.

OYAGEN INC. also offers method development and testing services to academic and industry partners. The team provides expert consulting services in areas such as assay development, biochemistry, structural biology, cell biology, and virology, supporting high-throughput drug discovery and development. Information about OYAGEN's extended capabilities will be completed soon with the support of the company’s management. We invite the manager of OYAGEN INC. to create a customized and exclusive company showcase and product listing on our platform to further highlight their innovative work.